Recent Updates
Recently added Catalysts

-praliciguat

Phase 1

Healthy Volunteers | Small molecule | Other |Cyclerion Therapeutics, Inc.|Last Updated: Jun 19, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment8
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03818295A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersPHASE1 COMPLETED 8 — — Mar 1, 2019Apr 24, 2019Jun 19, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Amount of total radioactivity excreted in urine (Aeu) and feces (Aef)
up to Day 15
Cumulative Aeu and cumulative Aef
up to Day 15
Percentage of total radioactivity excreted in urine (feu) and feces (fef)
up to Day 15
Cumulative feu and cumulative fef
up to Day 15
Percentage of total radioactivity in total excreta (feces + urine)
up to Day 15
Area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) of praliciguat in plasma
up to Day 15
AUC0-inf of total radioactivity in plasma and whole blood
up to Day 15
AUC from time zero to the last quantifiable concentration (AUC0-last) of praliciguat in plasma
up to Day 15
AUC0-last of total radioactivity in plasma and whole blood
up to Day 15
Maximum observed concentration (Cmax) of praliciguat in plasma
up to Day 15
Cmax of total radioactivity in plasma and whole blood
up to Day 15
Time of Cmax (Tmax) of praliciguat in plasma
up to Day 15
Tmax of total radioactivity in plasma and whole blood
up to Day 15
Apparent terminal elimination half-life (t1/2) of praliciguat in plasma
up to Day 15
t1/2 total radioactivity in plasma and whole blood
up to Day 15
Apparent total clearance of praliciguat (CL/F)
up to Day 15
Apparent volume of distribution of praliciguat (Vz/F)
up to Day 15
AUC0-inf of plasma praliciguat concentration relative to AUC0-inf of plasma total radioactivity (AUC0-inf Ratio of Plasma Praliciguat/Plasma Total Radioactivity)
up to Day 15
AUC0-inf of whole blood total radioactivity to AUC0-inf of plasma total radioactivity (AUC0-inf Ratio of Blood Total Radioactivity/Plasma Total Radioactivity)
up to Day 15
Secondary Endpoints
Levels of metabolite radioactivity excreted in urine and feces
up to Day 15
AUC0-inf of metabolite radioactivity levels in plasma
up to Day 15
AUC0-inf of plasma metabolite radioactivity levels relative to AUC0-inf of plasma total radioactivity (Plasma AUC0-inf Ratio of Metabolite Radioactivity/Total Radioactivity)
up to Day 15
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeOTHER
Treatment Arms
ArmTypeDescription
Healthy Male VolunteersEXPERIMENTALSingle oral dose of \[14C\]-praliciguat
Interventions
NameTypeDescription
[14C]-praliciguatDRUG10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Males of any race, between 18 and 55 years of age, inclusive * Body mass index between 18 and 32 kg/m2, inclusive * Subject is in good health and has no clinically significant findings on physical examination * Men must agree to use protocol-specified contraception and also to...

Countries:United States
Unlock Eligibility Criteria